Agilent Technologies (NYSE:A) PT Raised to $90.00 at Oppenheimer

Agilent Technologies (NYSE:AFree Report) had its price objective increased by Oppenheimer from $67.00 to $90.00 in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI reduced their target price on shares of Agilent Technologies from $135.00 to $132.00 and set an in-line rating on the stock in a research note on Wednesday, February 28th. Barclays raised their price target on shares of Agilent Technologies from $120.00 to $125.00 and gave the stock an underweight rating in a research note on Wednesday, February 28th. Citigroup raised their price target on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a neutral rating in a research note on Wednesday, February 28th. Bank of America downgraded shares of Agilent Technologies from a buy rating to a neutral rating and raised their price target for the stock from $130.00 to $133.00 in a research note on Tuesday, December 12th. Finally, UBS Group raised their price target on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a neutral rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Agilent Technologies currently has a consensus rating of Moderate Buy and a consensus price target of $138.29.

Read Our Latest Stock Report on A

Agilent Technologies Trading Down 0.8 %

Shares of A opened at $144.41 on Tuesday. Agilent Technologies has a twelve month low of $96.80 and a twelve month high of $151.58. The company has a market cap of $42.32 billion, a P/E ratio of 34.38, a P/E/G ratio of 4.46 and a beta of 1.11. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. The company’s fifty day simple moving average is $137.32 and its 200-day simple moving average is $125.92.

Agilent Technologies (NYSE:AGet Free Report) last announced its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The business had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the prior year, the firm posted $1.37 earnings per share. The business’s revenue for the quarter was down 5.5% on a year-over-year basis. As a group, analysts expect that Agilent Technologies will post 5.51 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be paid a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.38%.

Insider Buying and Selling

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 52,297 shares of Agilent Technologies stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the sale, the chief executive officer now directly owns 253,909 shares in the company, valued at approximately $38,086,350. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Agilent Technologies news, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the completion of the transaction, the vice president now directly owns 21,329 shares of the company’s stock, valued at $3,178,021. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the transaction, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at $38,086,350. The disclosure for this sale can be found here. Insiders sold 58,783 shares of company stock worth $8,803,238 in the last three months.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in A. OFI Invest Asset Management acquired a new position in shares of Agilent Technologies during the 3rd quarter worth approximately $25,000. Livelsberger Financial Advisory acquired a new position in Agilent Technologies in the 4th quarter valued at $26,000. Money Concepts Capital Corp acquired a new position in Agilent Technologies in the 4th quarter valued at $26,000. MV Capital Management Inc. raised its stake in Agilent Technologies by 120.7% in the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 105 shares during the last quarter. Finally, VisionPoint Advisory Group LLC acquired a new position in Agilent Technologies in the 4th quarter valued at $29,000.

About Agilent Technologies

(Get Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.